Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31231895 | 1.00 | PTPN1 (0.50) | PTPN1KDM4EGSK3BHTTALDH1A1 | |
| SCHEMBL14384453 | 0.85 | PTPN1 (0.61) | PTPN1KDM4EGSK3BHTTALDH1A1 | |
| SCHEMBL171862 | 0.83 | CYP11B1 (0.42) | PTPN1KDM4EGSK3BALDH1A1MAOB | |
| SCHEMBL4454971 | 0.78 | ALDH1A1 (0.47) | KDM4EALDH1A1MAOAMAOBKMT2A | |
| SCHEMBL23330765 | 0.75 | PTPN1 (0.50) | PTPN1KDM4EGSK3BHTTALDH1A1 | |
| SCHEMBL18936105 | 0.75 | ALDH1A1 (0.42) | KDM4EHTTALDH1A1KCNA3HSD17B10 | |
| SCHEMBL789581 | 0.75 | ALDH1A1 (0.51) | PTPN1KDM4EHTTALDH1A1MAOA | |
| SCHEMBL2091508 | 0.75 | PTPN1 (0.50) | PTPN1KDM4EHTTALDH1A1MAOA | |
| SCHEMBL2090321 | 0.75 | PTPN1 (0.50) | PTPN1KDM4EGSK3BHTTMAOA | |
| SCHEMBL31405756 | 0.75 | ALDH1A1 (0.51) | PTPN1KDM4EHTTALDH1A1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250320201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12312341-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-12084434-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240158376-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| CN-117813293-A | Urea derivatives useful for the treatment of cancer | 蝎子疗法股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4334298-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | Scorpion Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-1373259-B1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | PFIZER INC | 2004-10-07 | — | — | US | disclosed |
| CN-1505514-A | Combination of aldose reductase inhibitors with cyclooxygenase-2 inhibitors | �Ʒ� | 2004-06-16 | — | — | CN | disclosed |
| EP-1392310-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | Pfizer Products Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1373259-A1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030162784-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2003-08-28 | — | — | US | disclosed |
| US-6579879-B2 | Pyridazinone aldose reductase inhibitors | PFIZER INC | 2003-06-17 | — | — | US | disclosed |
| WO-2002087584-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002079198-A1 | PYRIDAZINONE ALDOSE REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | PIK3CA, PIK3CG, PIK3CD | PTPN1 1954/4885KDM4E 1411/4885GSK3B 178/4885 |
| US-20240158376-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | PTPN1 967/4885KDM4E 2471/4885GSK3B 39/4885 |
| US-20030162784-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, ALDOA, AKR1B1 | PTPN1 1807/4885KDM4E 2331/4885GSK3B 106/4885 |
| US-20020143017-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, AKR1B1, AKR1D1 | PTPN1 1843/4885KDM4E 2148/4885GSK3B 212/4885 |
| US-12312341-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | PTPN1 967/4885KDM4E 2471/4885GSK3B 39/4885 |
| US-20250320201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | PTPN1 3311/4885KDM4E 104/4885GSK3B 3507/4885 |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | ALDOA, ALDH2, AKR1B1 | PTPN1 2672/4885KDM4E 3088/4885GSK3B 1291/4885 |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | PTPN1 967/4885KDM4E 2471/4885GSK3B 39/4885 |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | PTPN1 967/4885KDM4E 2471/4885GSK3B 39/4885 |
| US-12084434-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | PTPN1 967/4885KDM4E 2471/4885GSK3B 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.